New study has examined levels of SRRM2 phosphorylation in a mouse model of Alzheimer's disease (AD), and found that they increased prior to Aβ aggregation. The findings of the study were carried out by a Japanese team of researchers led by Tokyo Medical and Dental University (TMDU).
Alzheimer's disease (AD) is the most common form of dementia, involving memory loss and a reduction in cognitive abilities. Patients with AD develop multiple abnormal protein structures in their brains that are thought to destroy or damage nerve cells (neurons). One of these structures, the senile plaque, is made up of clumps of beta-amyloid (Aβ) peptide which form in the spaces between neurons.
‘New study offers a fresh insight into early changes that occur during Alzheimer’s disease pathology involving splicing proteins, suggesting possibilities for gene therapies by virus vectors.’
Many advanced clinical trials in patients with AD have attempted to slow down or reverse the disease by targeting these plaques for removal. However, despite the successful decrease in Aβ aggregation, these trials mostly have failed to improve memory or cognitive function in AD patients.
Before the formation of Aβ aggregates, studies revealed changes in the phosphorylation (a chemical modification) of certain proteins, including SRRM2. This protein was thought to be involved in a form of gene regulation known as splicing, but its exact function was unclear.
This ultimately prevented the nuclear transport of SRRM2 and led to reduced levels of PQBP1 protein, which has been linked with the neurodevelopmental and intellectual disorders. The study results were reported in Molecular Psychiatry.
"We showed that the increased phosphorylation of SRRM2 prevented it from interacting with another protein which aids protein folding," says first author Hikari Tanaka. "In the absence of this interaction, SRRM2 remained unfolded so was not transported to the nucleus and was degraded in the cytoplasm."
The team next measured levels of SRRM2 and PQBP1 protein in the cerebral cortex of early-phase AD mice and human end-stage AD patients as well as in human AD iPS cells. Both proteins were greatly reduced compared with corresponding amounts in healthy controls.
"To find out what effect a reduction in PQBP1 would have in vivo, we generated knockout mice in which the PQBP1 gene was disrupted," explains corresponding author Hitoshi Okazawa. "We observed cognitive decline and changes in the morphology of their synapses, which are junctions between neurons that allow electrical and chemical communication. These changes were caused by disrupted patterns of synapse gene splicing."
A viral vector containing PQBP1 was used to recover the synapse protein expression in these mice. Not only did this restore PQBP1 expression, but it also recovered the abnormal phenotypes.